Waters Corp (WAT) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Waters Corporation [indiscernible] 2025 Financial Results Conference Call. (Operator Instructions) This call is being recorded. If anyone has any objections, please disconnect at this time. It is now my pleasure to turn the call over to Mr. Caspar Tudor, Head of Investor Relations.

    早安,歡迎參加 Waters Corporation [聽不清] 2025 年財務業績電話會議。(接線員指示) 本通話將被錄音。如有任何異議,請此刻中斷連線。現在我很榮幸將電話交給投資人關係主管 Caspar Tudor 先生。

  • Please go ahead, sir.

    先生,請開始。

  • Caspar Tudor - Head of Investor Relations

    Caspar Tudor - Head of Investor Relations

  • And good morning, everyone. Welcome to Waters Corporation's Fourth Quarter Earnings Call. Joining me today are Dr. Udit Batra, our President and Chief Executive Officer; and Amol Chaubal, our Senior Vice President and Chief Financial Officer. Before we begin, I will cover the cautionary language.

    各位早安。歡迎參加 Waters Corporation 第四季財報電話會議。今天與我一同出席的有:我們的總裁暨執行長 Udit Batra 博士,以及資深副總裁暨財務長 Amol Chaubal。在開始之前,我先說明警語聲明。

  • In this conference call, we will make various forward-looking statements regarding future events or future financial performance of the company, including the expected financial and operational impact of what is combination with the Biosciences and Diagnostic Solutions business of Becton, Dickinson and Company. We will provide guidance regarding possible future results, as well as commentary on potential market and business conditions that may impact Waters Corporation over the first quarter of 2026 and full year 2026.

    在本次電話會議中,我們將就公司未來事件或未來財務表現發表各項前瞻性陳述,包括與 Becton, Dickinson and Company 的生物科學與診斷解決方案事業之結合對財務與營運的預期影響。我們將提供可能的未來業績指引,並就可能影響 Waters Corporation 於 2026 年第一季及 2026 全年之市場與業務狀況提出評論。

  • These statements are only our present expectations and are subject to risks and uncertainties. Please see the risk factors included within our Form 10-K, our Form 10-Qs, our other SEC filings and the cautionary language included in this morning's earnings release. During today's call, we will refer to certain non-GAAP financial measures.

    這些陳述僅代表我們目前的預期,並受風險與不確定性影響。請參閱我們的 Form 10-K、Form 10-Q、其他向 SEC 提交之文件中的風險因素,以及今早財報新聞稿所載之警語聲明。在今天的電話會議中,我們將提及若干非 GAAP 財務衡量指標。

  • Reconciliations to the most directly comparable GAAP measures are attached to our earnings release and in the appendix of the slide presentation accompanying today's call. Unless stated otherwise, references to quarterly results increasing or decreasing are in comparison to the fourth quarter of calendar year 2024.

    與最直接可比之 GAAP 指標的調節表已附於我們的財報新聞稿,並收錄於今日電話會議隨附簡報的附錄中。除非另有說明,對於季度業績增加或減少的提及,均係與 2024 曆年第四季相比。

  • In addition, unless stated otherwise, all year-over-year revenue growth rates and ranges given on today's call are on a comparable constant currency basis, and all quarter-over-quarter revenue growth rates and ranges on a comparable constant currency basis.

    此外,除非另有說明,今日電話會議所提供之所有年對年營收成長率與區間,均以可比的固定匯率基礎計算;所有季對季營收成長率與區間亦以可比的固定匯率基礎計算。

  • Finally, we do not intend to update our guidance, predictions or projections, except as part of a regularly scheduled earnings release or as otherwise required by law. I would now like to turn the call over to Udit to begin with our key messages for the quarter. Over to you, Udit.

    最後,除作為例行的財報發布之一部分或法律另有要求外,我們無意更新我們的指引、預測或推估。現在我想把電話交給 Udit,請他先分享本季的重點訊息。交給你了,Udit。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Thank you, Caspar, and good morning, everyone. We delivered a strong finish to the year, achieving high single-digit reported revenue growth and low double-digit adjusted EPS growth in the fourth quarter. This reflects yet another quarter of industry-leading sales growth. Today also marks a transformative step forward as we complete the acquisition of BD's Biosciences and Diagnostic Solutions business. We are uniting world-class expertise across chemistry, physics and biology into a scientific powerhouse with category-defining brands and a shared culture of pioneering innovation.

    謝謝你,Caspar,各位早安。我們在年底交出強勁收官,第四季達成以報告基礎計算的高個位數營收成長,以及經調整 EPS 的低雙位數成長。這反映了我們又一季的業界領先銷售成長。今天同時也標誌著一個具轉型意義的重大進展:我們完成收購 BD 的生物科學與診斷解決方案事業。我們正把化學、物理與生物領域的世界級專業整合為一個科學強權,擁有定義品類的品牌,以及共同的開創性創新文化。

  • We look forward to welcoming our new colleagues later this morning. It also marks the point at which we will have full operational control over the convey business. With months of rigorous integration planning behind us, we're now moving immediately into execution, applying the same focus and discipline that have driven exceptional results at Waters. We are entering this chapter from a position of strength. Throughout 2025, we have advanced the strategic road map that we laid out five years ago.

    我們期待在今天稍晚迎接新同仁加入。這也標誌著我們將全面取得對 convey 業務的營運控制權的時點。在歷經數月嚴謹的整合規劃後,我們現在立即進入執行階段,運用同樣的專注與紀律,這些正是推動 Waters 取得卓越成果的關鍵。我們以強勢的姿態進入這個新篇章。在整個 2025 年,我們持續推進五年前所擘劃的策略路線圖。

  • Commercial execution continues to strengthen with KPIs running ahead of the commitment we made at our March 2025 Investor Day. Innovation remains a powerful growth driver as we launch a new wave of pioneering innovation. Our unique exposure to high-volume testing opportunities across GLP-1s, PFAS and India generics, again, outpaced expectations.

    商業執行力持續強化,各項 KPI 的表現領先我們在 2025 年 3 月投資人日所做的承諾。創新仍是強勁的成長驅動力,因為我們推出新一波的開創性創新。我們在 GLP-1、PFAS 以及印度學名藥等高量測試機會上的獨特曝險,再次超出預期。

  • We secured key wins in our transition to Empower as a subscription-based model, and we continue to expand deliberately into our high-growth adjacencies like bioseparations and bioanalytical characterization. These outcomes reflect the strength and discipline of our simple, repeatable business model serving high-volume regulated growth markets.

    我們在將 Empower 轉型為訂閱制模式的過程中取得關鍵勝利,並持續有計畫地擴展至生物分離與生物分析特性鑑定等高成長相鄰領域。這些成果反映了我們簡單、可複製的商業模式之實力與紀律,服務於高量、受監管的成長型市場。

  • They also reflect the dedication of our team whose focus on customers, science and operational excellence continues to differentiate Waters. Now turning to the quarter. As reported sales and adjusted EPS landed at the high end of our guidance range. Sales grew 7% on a reported basis and 6% in constant currency, driven by high single-digit growth across our pharma and industrial end markets. Adjusted EPS grew low double digits to $4.53, on a GAAP basis, EPS was $3.77.

    這也反映了我們團隊的投入;他們對客戶、科學與營運卓越的專注,持續讓 Waters 脫穎而出。接著談本季表現。以報告口徑計,銷售與經調整 EPS 均落在我們指引區間的高端。銷售以報告基礎成長 7%,以固定匯率計成長 6%,主要由我們製藥與工業終端市場的高個位數成長所帶動。經調整 EPS 以低雙位數成長至 4.53 美元;以 GAAP 口徑計,EPS 為 3.77 美元。

  • Recurring revenue grew 9%, led by chemistry growth. Instruments grew 3%, led by yet again high single-digit LCMS growth. TA instruments declined for the quarter due to cautious spending in US and Europe. During the quarter, we achieved strong wins in our transition to a subscription-based model for Empower, with successful adoption across multiple large pharma customers.

    經常性收入成長 9%,由化學業務成長領軍。儀器收入成長 3%,其中 LCMS 再度以高個位數成長領先。TA 儀器本季下滑,原因是美國與歐洲支出趨於審慎。本季我們在將 Empower 轉型為訂閱制模式方面取得強勁進展,並在多家大型製藥客戶中成功導入。

  • While this reduced our overall instrument growth rate by a low single-digit percentage for the quarter, it reflects a strategically attractive shift to a model with superior economics. Together with our new feature releases, this supports accretive tailwinds in 2027 with the incremental recurring revenue that it brings.

    雖然這使我們本季整體儀器成長率降低了低個位數百分點,但這反映了向具更佳經濟效益之模式轉移的策略吸引力。結合我們的新功能釋出,這將在 2027 年帶來正向增益的順風,來自其所帶來的新增經常性收入。

  • For the full year, sales grew 7% on both a reported and constant currency basis. Recurring revenue grew 8%, driven by 12% growth in chemistry. Instrument revenue grew 5%, led by LC-MS, which grew high single digits or better every quarter of the year.

    全年而言,銷售以報告基礎與固定匯率基礎均成長 7%。經常性收入成長 8%,主要由化學業務 12% 的成長所驅動。儀器收入成長 5%,由 LC-MS 帶動,且 LC-MS 在全年每一季皆達到高個位數或更高的成長。

  • Adjusted EPS grew 11% to $13.13, supported by top line strength, operational excellence and effective tariff mitigation. GAAP EPS was $0.76. Let me now highlight the drivers behind our strong performance and why we expect the strong momentum to continue into 2026. Starting with commercial execution.

    經調整 EPS 成長 11% 至 13.13 美元,受惠於營收端的強勁表現、營運卓越以及有效的關稅緩解措施。GAAP EPS 為 0.76 美元。接下來我將重點說明我們強勁表現背後的驅動因素,以及我們為何預期這股強勁動能將延續至 2026 年。先從商業執行談起。

  • Our KPIs continue to run ahead of external commitments, and we're progressing well towards our long-term targets.

    我們的各項 KPI 持續優於對外承諾,並正穩健朝向長期目標推進。

  • Within instrument replacement, momentum continues to build. Instrument growth is now tracking at 2.5% CAGR approximately versus 2019, up roughly 100 basis points since the start of the replacement cycle. This reflects a steady mean reversion towards the long-term historical instrument growth rate of 5%.

    在儀器汰換方面,動能持續累積。相較於 2019 年,儀器成長目前約以 2.5% 的年複合成長率(CAGR)推進,自汰換週期開始以來約提升 100 個基點。這反映了穩健地回歸至長期歷史儀器成長率 5% 的均值。

  • Service plan attachment increased to 54%, reflecting approximately 400 basis points of improvement in a single year. This is the strongest annual expansion we have ever delivered and sets us up for above-average service growth in 2026, supported by the associated revenue pull-through.

    服務方案附掛率提升至 54%,反映單一年內約 400 個基點的改善。這是我們有史以來最強的年度擴張幅度,並在相關收入帶動效應的支持下,為 2026 年高於平均的服務成長奠定基礎。

  • E-commerce penetration reached approximately 45% of consumables revenue, driving a growth tailwind along with new products across our chemistry portfolio. Contract organizations now represent 27% of pharma sales, up from 15% five years ago, positioning us well among diversified sources of CapEx.

    電子商務滲透率達到約耗材收入的 45%,並與我們化學產品組合中的新產品一同帶來成長順風。委外合約機構目前占製藥銷售的 27%,高於五年前的 15%,使我們在多元化資本支出(CapEx)來源方面具備良好定位。

  • Innovation is also augmenting our results. Strong growth from new products launched over the past several years has continued to compound, alongside a new wave of innovation launched throughout 2025. For the full year, Alliance iS HPLC sales more than doubled, reflecting strong adoption of our flagship platform, which reduces errors by up to 40% in QC labs.

    創新也正在提升我們的業績。過去數年推出的新產品所帶來的強勁成長持續複利增長,同時我們在 2025 年全年推出了新一波創新。就全年而言,Alliance iS HPLC 銷售額超過翻倍,反映市場對我們旗艦平台的強勁採用;該平台可在 QC 實驗室將錯誤率降低最高達 40%。

  • Xevo TQ Absolute mass spec platforms grew over 30%, driven by PFAS demand and the launch of the Absolute XR, which sets a new benchmark for robustness, together with class-leading sensitivity. Max peak Premier Chemistry grew over 35%, underscoring the significant impact our technology has brought to the industry for larger and more complex molecules.

    Xevo TQ Absolute 質譜平台成長超過 30%,主要受 PFAS 需求帶動,並受惠於 Absolute XR 的推出;該產品在堅固耐用性方面樹立新標竿,同時具備同級領先的靈敏度。Max peak Premier Chemistry 成長超過 35%,凸顯我們的技術為產業在更大、更複雜分子方面帶來的重大影響。

  • Our successful strategy of entering high-growth areas further enhanced our results in 2025. In bioanalytical characterization, adoption of light scattering and BioAccord continues to build in pharma process development and quality control applications. With the launch of Xevo CDMS, we are now expanding this position to routine characterization of mega molecules such as ADCs and viral vectors.

    我們成功切入高成長領域的策略,進一步強化了 2025 年的業績表現。在生物分析表徵方面,光散射與 BioAccord 的採用持續提升,應用於製藥製程開發與品質控制。隨著 Xevo CDMS 的推出,我們正將此優勢擴展至對 ADC 與病毒載體等巨分子的例行表徵。

  • In bioseparations, we built on the success of Max peak Premier inert surfaces with a new generation of products designed to separate complex large molecules. These include SEC columns for viral vectors, [slalom] chromatography for large oligonucleotides and affinity-based separations using specific antibodies. These new products have accelerated chemistry growth to double digits in 2025, meaningfully above our 7% historical average growth rate.

    在生物分離領域,我們在 Max peak Premier 惰性表面成功的基礎上,推出新一代產品,專為分離複雜的大分子而設計。其中包括用於病毒載體的 SEC 色譜柱、用於大型寡核苷酸的 [slalom] 色譜,以及使用特異性抗體的親和式分離。這些新產品使 2025 年化學品業務成長加速至雙位數,顯著高於我們歷史平均 7% 的成長率。

  • For LC-MS into diagnostics, we have continued to grow our assay menu, launching IBD products covering 12 new analytes in endocrinology, and four new analytes in therapeutic drug monitoring over the past two years. Turning to our idiosyncratic growth drivers.

    在面向診斷的 LC-MS 方面,我們持續擴充檢測項目(assay menu);過去兩年推出 IBD 產品,涵蓋內分泌領域 12 項新分析物,並在治療藥物監測新增 4 項分析物。接下來談我們的特有成長驅動因素。

  • In 2025, these drivers contributed more than 300 basis points of growth, all tracking ahead of our commitments. GLP-1 testing-related revenue more than doubled, contributing approximately 100 basis points of year-over-year growth. This reflects continued wins in development and manufacturing across the globe, supported by our specced-in position for both oral and injection-based doses.

    在 2025 年,這些驅動因素合計貢獻超過 300 個基點的成長,且均優於我們的承諾目標。與 GLP-1 檢測相關的營收超過翻倍,約貢獻 100 個基點的年增成長。這反映我們在全球研發與製造端持續取得勝利,並受惠於我們在口服與注射劑型的「規格導入」(specced-in)地位。

  • PFAS testing growth remained robust, increasing more than 40% year-over-year and adding roughly 80 basis points of growth. Demand was broad-based driven by an expanding regulatory landscape that is evolving towards food, materials and consumer product testing.

    PFAS 檢測成長仍然強勁,年增超過 40%,並增加約 80 個基點的成長貢獻。需求呈現廣泛性,主要由不斷擴大的監管環境所驅動,且監管正演進至食品、材料與消費性產品檢測。

  • India, again, delivered strong performance. Ex GLP-1 revenue grew low teens, increasing by approximately $40 million and contributing around 130 basis points of growth, tied to the ongoing patent cliff of blockbuster drugs. Taken together, we grew 7% in 2025 with all regions delivering mid-single-digit growth or better. Pharma revenue grew 9% with high single-digit growth across Americas and Europe, and low double-digit growth in Asia. In pharma -- in non-pharma end markets, industrial grew 6%, while A&G declined 1%.

    印度再次交出強勁表現。扣除 GLP-1 後的營收以十位數低段成長,增加約 4,000 萬美元,並貢獻約 130 個基點的成長,與重磅藥物專利到期潮(patent cliff)持續發酵相關。綜合而言,我們在 2025 年成長 7%,所有地區均達到或優於中個位數成長。製藥營收成長 9%,美洲與歐洲為高個位數成長,亞洲為低雙位數成長。在製藥以外的終端市場中,工業成長 6%,而 A&G 下滑 1%。

  • In China, we grew 9% for the year. Our team delivered exceptional performance by capturing renewed momentum in biotech and CDMOs, executing well in food and environmental applications and winning a series of academic and government stimulus centers.

    在中國,我們全年成長 9%。我們的團隊透過掌握生技與 CDMO 的回溫動能、在食品與環境應用上執行到位,並贏得一系列學術與政府刺激方案中心的訂單,交出卓越表現。

  • As we now move into 2026, we expect continued organic strength supported by the instrument replacement cycle and contribution from new product innovation. We're also expanding our idiosyncratic growth driver framework from three drivers to five. In addition to GLP-1s, PFAS and India generics, we're adding biologics and informatics.

    展望 2026 年,我們預期在儀器汰換週期與新產品創新貢獻的支持下,有機成長動能將持續強勁。我們也將特有成長驅動因素的框架由三項擴增至五項。除 GLP-1、PFAS 與印度學名藥外,我們新增生物製劑(biologics)與資訊學(informatics)。

  • Biologics reflects future growth linked to bioseparations and bioanalytical characterization from progress we have already made in our high-growth adjacencies before the closing of the transaction. In bioseparations we anticipate sustained strength driven by new chemistry products already launched and in our near-term road map serving large molecule and novel modality applications. In bioanalytical characterization, we anticipate continued placement of LC-MS, malls and CDMS in process development and in QA/QC.

    生物製劑反映未來成長,與我們在交易完成前已於高成長相鄰領域取得的進展相關,並連結至生物分離與生物分析表徵。在生物分離方面,我們預期在已推出的新化學產品,以及近期產品路線圖(road map)對大分子與新型態(novel modality)應用的服務帶動下,維持強勁動能。在生物分析表徵方面,我們預期 LC-MS、malls 與 CDMS 將持續在製程開發及 QA/QC 中擴大裝機。

  • There is potential upside beyond our current assumptions supported by the FDA's draft biosimilars guidance, which could drive incremental demand by shifting approvals towards comparative analytical assessment rather than clinical outcome studies. For informatics, this reflects the future expected incremental growth linked to the phased transition of Empower from our legacy license-based model to our subscription-based offering.

    在我們目前假設之外仍存在上行空間;FDA 的生物相似藥(biosimilars)指引草案可能帶動額外需求,因其可能使核准更偏向比較性分析評估,而非臨床結果研究。至於資訊學,這反映未來預期的增量成長,來自 Empower 由傳統授權(license)模式分階段轉向訂閱(subscription)方案。

  • As we have shared previously, we expect to take our informatics business from its present revenue base of approximately $300 million to approximately $500 million by 2030. The move towards subscription comes with a shift in revenue timing. Under this transition, revenue is recognized consistently over the life of the contract rather than upfront.

    如我們先前所分享,我們預期到 2030 年,資訊學業務將由目前約 3 億美元的營收基礎提升至約 5 億美元。轉向訂閱將伴隨營收認列時點的改變。在此轉型下,營收將在合約期間內按期一致認列,而非一次性提前認列。

  • For a typical customer converting to subscription, the breakeven point where cumulative subscription revenue equals the prior license value is reached in approximately 18 months. From that point forward, it adds incremental high-quality recurring revenue with a long-term visibility and margin benefits.

    對於典型由授權轉為訂閱的客戶而言,累計訂閱營收等同於先前授權價值的損益兩平點,約在 18 個月達成。自該時點起,將帶來額外的高品質經常性營收,並具備長期可視性與毛利率效益。

  • We are executing this change gradually and expect it to become a more positive structural driver in the years ahead, beginning in 2027. Taken together, these five drivers are expected to contribute over 200 basis points of annual revenue growth accretion on a stand-alone basis between now and 2030.

    我們正逐步推進此變革,並預期自 2027 年起,在未來數年將成為更正向的結構性驅動因素。綜合而言,這五項驅動因素預期在現在至 2030 年間,以獨立運作(stand-alone)基礎每年可貢獻超過 200 個基點的營收成長增量。

  • Turning now to our integration of BD Biosciences and Diagnostic Solutions. This combination is a significant value creation opportunity that further adds to our attractive trajectory across two main dimensions. Firstly, it strengthens our position in high-growth adjacencies across bioseparations and bioanalytical characterization by adding critical technologies and expertise.

    接下來談我們對 BD Biosciences 與 Diagnostic Solutions 的整合。此一結合是重要的價值創造機會,並在兩個主要面向進一步強化我們具吸引力的成長軌跡。首先,透過加入關鍵技術與專業能力,它強化了我們在生物分離與生物分析表徵等高成長相鄰領域的地位。

  • It also adds to our LC-MS diagnostics business with day one commercial scale, customer channel access and automation capabilities. Secondly, it provides a meaningful execution uplift opportunity by applying our operating discipline across instrument replacement, e-commerce adoption and service attachment, we expect to replicate the same growth acceleration that we have successfully achieved in our existing businesses.

    它也為我們的 LC-MS 診斷業務帶來「第一天」即可具備的商業規模、客戶通路觸達與自動化能力。其次,透過將我們的營運紀律應用於儀器汰換、電商採用與服務綁定(service attachment),它提供顯著的執行力提升機會;我們預期可複製在既有業務中已成功達成的同樣成長加速。

  • Together, this positions Waters for sustainable, high single-digit growth over the long term, and well beyond the current instrument replacement cycle. The transaction also yields attractive cost synergies. Our baseline plan represents less than 5% of the combined cost base with the potential to exceed that level.

    綜合而言,這使 Waters 在長期具備可持續的高個位數成長,且可延伸至本次儀器汰換週期之後。該交易亦帶來具吸引力的成本綜效。我們的基準計畫占合併後成本基礎不到 5%,且有機會超越該水準。

  • Consistent with market benchmarks for deals of size and prior large-scale integrations that our leadership team have successfully executed. To ensure we capture this value quickly and consistently, we have aligned the organization around a new operating structure. We have organized Waters into four divisions, where each follows our repeatable business model with simple yet sophisticated instruments, compliance software, customized consumables and world-class service.

    這與同規模交易的市場基準一致,也符合我們領導團隊先前成功執行的大型整合經驗。為確保我們能快速且一致地掌握此價值,我們已圍繞新的營運架構對組織進行對齊。我們將 Waters 組織為四個事業部,各事業部皆遵循我們可複製的商業模式:簡潔而精密的儀器、合規軟體、客製化耗材與世界級服務。

  • This structure enhances accountability and will provide investors with a clear transparent view into the performance of all our key segments across the company. First, Waters Analytical Sciences, formerly known as Waters Division, will continue to be led by Rob Carpio, who you all know well.

    此架構提升問責性,並將為投資人提供清晰透明的視角,以檢視公司各關鍵部門的表現。首先,Waters Analytical Sciences(原稱 Waters Division)將持續由各位熟悉的 Rob Carpio 領導。

  • The division comprises LC, mass spec, light scattering and particle analysis, together with our Empower informatics platform, chemistry consumables and our service team. Going forward, revenue from Water's Clinical Business will be reported within our Advanced Diagnostics division. Waters Biosciences, formerly BD Biosciences, will be led by Steve Conley, who has led the business for the past 3.5 years, and has played a key role in the launch of its next-generation flow cytometry platforms.

    該事業部涵蓋 LC、質譜、光散射與粒子分析,並結合我們的 Empower 資訊平台、化學耗材以及服務團隊。展望未來,Waters 的臨床業務收入將在我們的先進診斷事業部內報告。Waters 生物科學(原 BD Biosciences)將由 Steve Conley 領導;他在過去 3.5 年一直領導該業務,並在其下一代流式細胞儀平台的推出中扮演關鍵角色。

  • The Waters Biosciences division consists of leading flow cytometry brands like Fax Discover and (technical difficulty), the Horizon (inaudible) brand of fluorescent dyes and reagents and(technical difficulty)software. Waters Advanced Diagnostics will be led by (technical difficulty) Bennett, who has been running our Clinical and TA business unit over the past several years, and has transformed the top line growth profile of these businesses.

    Waters 生物科學事業部由領先的流式細胞術品牌組成,例如 Fax Discover 與(技術問題),以及 Horizon(聽不清)品牌的螢光染料與試劑,並包含(技術問題)軟體。Waters 先進診斷事業部將由(技術問題)Bennett 領導;他在過去數年負責我們的臨床與 TA 事業單位,並改變了這些業務的營收成長輪廓。

  • (technical difficulty) has a strong background in diagnostics, having served as Senior Vice President of High Growth Markets at [Beckman Coulter] Diagnostics before joining Waters. The Waters Advanced Diagnostics division consists of leading microbiology testing brands, including Bactec, Phoenix and Kaster, as well as molecular diagnostic solutions with the Max and core platforms, LC-MS based solutions and point-of-care testing.

    (技術問題)在診斷領域具備深厚背景,在加入 Waters 之前曾於 [Beckman Coulter] Diagnostics 擔任高成長市場資深副總裁。Waters 先進診斷事業部由領先的微生物檢測品牌構成,包括 Bactec、Phoenix 與 Kaster,並提供以 Max 與 core 平台為基礎的分子診斷解決方案、以 LC-MS 為基礎的解決方案,以及定點照護(point-of-care)檢測。

  • Waters Material Sciences, formerly TA division will be led by Dan Rush on an interim basis while we appoint a successor to -- Dan is our Senior Vice President of Strategy and Transformation and has a long history of leading commercial and strategy teams. He served as Vice President of worldwide commercialization strategy and innovation at [Bristol-Myers Squibb] before joining Waters in 2021.

    Waters 材料科學(原 TA 事業部)將由 Dan Rush 暫代領導,直到我們任命繼任者為止——Dan 是我們的策略與轉型資深副總裁,長期領導商務與策略團隊。他在 2021 年加入 Waters 之前,曾於 [Bristol-Myers Squibb] 擔任全球商業化策略與創新副總裁。

  • The Material Sciences division consists of products, services and informatics spanning a diverse range of materials characterization techniques, including thermal analysis, rheology and microcalorimetry. These are used in a range of applications such as battery testing for electric vehicles, pharma and medical devices. Together, these businesses bring leading scientific capabilities serving customers in high-volume regulated applications.

    材料科學事業部提供橫跨多元材料表徵技術的產品、服務與資訊解決方案,包括熱分析、流變學與微量熱法。這些技術應用於多種場景,例如電動車電池測試、製藥與醫療器材。綜合而言,這些業務帶來領先的科學能力,服務於高量且受監管的應用領域客戶。

  • They're anchored by a shared operating model that leverages category-defining brands and a universal culture of pioneering innovation. In parallel, we have aligned early execution priorities to hit the ground running now that we are gaining full operational control of the Biosciences and Diagnostic Solutions business.

    它們以共享的營運模式為基礎,運用具類別定義性的品牌,以及普遍的開創性創新文化。同時,隨著我們正取得對生物科學與診斷解決方案業務的完整營運控制權,我們已對齊早期執行優先事項,以便立即展開行動。

  • With several months of integration planning behind us, we have clear line of sight to the initiatives that will drive the most value in the early innings of the integration. In the most recent quarter, BD Biosciences and Diagnostic Solutions results came in below expectations due to impacts that became apparent during the quarter.

    在完成數月的整合規劃後,我們已清楚掌握在整合初期將驅動最大價值的各項舉措。在最近一季,BD Biosciences 與 Diagnostic Solutions 的業績低於預期,原因是一些影響在該季期間才變得明顯。

  • In China, demand weakened due to increased focus on reducing consumption and diagnostics testing, while the US government shutdown affected the Biosciences business as export approvals got delayed. At the same time, the point-of-care business was impacted by a milder flu season compared to the previous year.

    在中國,由於更加著重於降低耗材使用與診斷檢測,需求轉弱;同時,美國政府停擺影響了生物科學業務,因為出口核准遭到延遲。此外,與前一年相比較為溫和的流感季,也衝擊了定點照護業務。

  • As we look ahead, our cost and revenue synergies are firmly on track. In 2026, we will make swift and decisive progress towards achieving the objectives we've laid out. On cost synergies, restructuring, procurement savings and network optimization are key vectors that we expect to begin realizing this year. As a prudent starting assumption, we expect to realize approximately $55 million of adjusted EBIT from cost synergies in 2026. On revenue synergies, while there is meaningful opportunity across each of our work streams over time, our first priority in 2026 is enhancing commercial execution and forecasting discipline.

    展望未來,我們的成本與營收協同效益正穩健按計畫推進。在 2026 年,我們將迅速且果斷地朝著既定目標取得進展。在成本協同方面,重整、採購節省與網路優化是關鍵路徑,我們預期今年開始逐步實現。以審慎的起始假設,我們預期在 2026 年可由成本協同實現約 5,500 萬美元的調整後 EBIT。在營收協同方面,雖然隨時間推進各工作流皆存在可觀機會,但我們在 2026 年的首要任務是強化商業執行與預測紀律。

  • We will quickly begin to leverage untapped growth vectors in instrument replacement in e-commerce and service attachment and will immediately establish a deal desk to manage pricing discipline. As a prudent starting assumption, we expect to realize approximately $50 million in revenue, and $25 million in corresponding adjusted EBIT from revenue synergies in 2026.

    我們將迅速開始運用尚未充分開發的成長動能,包括儀器汰換、電子商務與服務綁定,並將立即設立交易審核小組(deal desk)以管理定價紀律。以審慎的起始假設,我們預期在 2026 年可由營收協同實現約 5,000 萬美元營收,以及相對應約 2,500 萬美元的調整後 EBIT。

  • Let me now describe the first phase of revenue synergy realization in a little bit more detail. These are the same levers you've seen us execute successfully at Waters over the past five years. Starting with instrument replacement.

    接下來我將更詳細說明營收協同實現的第一階段。這些都是你們在過去五年看到我們在 Waters 成功執行的相同槓桿。先從儀器汰換開始。

  • There are approximately 22,000 flow and back tech instruments that are ripe for replacement. At the same time, a meaningful wave of new products are being launched, such as Fax Discover -- and [Back Deck FXI]. To achieve our revenue synergy target of $20 million by year 5, we need to drive an incremental 100 instrument replacements per year.

    約有 22,000 台 flow 與 back tech 儀器已具備汰換時機。同時,一波重要的新產品正陸續推出,例如 Fax Discover——以及[Back Deck FXI]。為了在第 5 年達成 2,000 萬美元的營收協同目標,我們需要每年額外推動 100 台儀器汰換。

  • To put that into perspective, during our prior indomitable replacement initiative at Waters, we delivered double the target in half the time. Our service plan attachment -- for service plan attachment, our $20 million revenue synergy target can be achieved by increasing attachment by approximately 1 percentage point per year, a rate that is more than consistent with our historical performance of more than 2% annually over the past five years.

    作為對照,在我們先前於 Waters 推動的儀器汰換計畫中,我們用一半的時間達成了兩倍的目標。至於服務方案綁定——就服務方案綁定而言,我們 2,000 萬美元的營收協同目標可透過每年將綁定率提高約 1 個百分點來達成;這一速度完全符合我們過去五年每年超過 2% 的歷史表現。

  • For e-commerce, our target is to increase adoption by approximately 4% annually, which too is a more measured growth trajectory compared to our historical performance. I will now cover our 2026 guidance. Across our existing businesses, the team is executing well with a revitalized portfolio, leveraging instrument replacement and realizing benefits from our idiosyncratic growth drivers.

    在電子商務方面,我們的目標是每年將採用率提高約 4%,相較於我們的歷史表現,這同樣是較為保守的成長軌跡。接下來我將說明我們對 2026 年的指引。在我們既有業務方面,團隊正以重新活化的產品組合良好執行,運用儀器汰換並實現我們特有成長驅動因素所帶來的效益。

  • As a prudent starting point, these dynamics support organic constant currency revenue growth of 5.5% to 7%. Turning to the acquired business contribution.

    以審慎的起點來看,這些動態支持以固定匯率計的有機營收成長 5.5% 至 7%。接著談併購業務的貢獻。

  • Following today's expected close of the transaction, we expect the Biosciences and Diagnostic Solutions businesses to contribute $3 billion of revenue in 2026. While the majority of headwinds that impacted the business in 2025 are already in the baseline, we have further risk adjusted our outlook to ensure a prudent starting point.

    在今日預期完成交易交割後,我們預期生物科學與診斷解決方案業務在 2026 年將貢獻 30 億美元營收。雖然 2025 年影響該業務的大部分逆風已反映在基準之中,我們仍進一步對展望進行風險調整,以確保採取審慎的起始點。

  • We're assuming approximately 2.5% underlying growth in 2026 on an owned period basis before any benefit from execution and pricing improvements or planned organizational simplification. Taken together with the revenue synergies I just mentioned, this results in total 2026 reported revenue of approximately $6.405 billion to $6.455 billion. These starting assumptions imply a blended year-over-year revenue growth of approximately 5.3% at the midpoint of the combined company in 2026.

    我們假設在 2026 年、以持有期間(owned period)口徑計算,在尚未納入執行與定價改善或規劃中的組織簡化所帶來的效益之前,基礎成長約為 2.5%。再加上我剛提到的營收協同,這使得 2026 年合併後的報告營收約為 64.05 億至 64.55 億美元。這些起始假設意味著在 2026 年,合併公司於中位數的年增營收成長約為 5.3%。

  • This is an industry-leading growth guidance and carries clear opportunity for outperformance as the year progresses. From a profitability perspective, we expect to deliver a 2026 adjusted operating margin percentage of approximately 28.1%, which is already more than 100 basis points of margin expansion compared with our deal model in 2025.

    這是一項領先業界的成長指引,且隨著年度推進,具備明確的超預期空間。就獲利能力而言,我們預期 2026 年調整後營業利益率約為 28.1%,相較於我們 2025 年交易模型,已高出逾 100 個基點的利潤率擴張。

  • This translates to full year 2026 adjusted EPS of $14.30 to $14.50, which is also an attractive starting point, reflecting 8.9% to 10.4% growth. It includes $0.10 of accretion from the transaction versus Waters' adjusted EPS on a stand-alone basis even before reaching a full year of ownership. With that, I will now turn the call over to Amol to review the financials and walk through our guidance in more detail.

    這對應到 2026 全年調整後 EPS 為 14.30 至 14.50 美元,這同樣是一個具吸引力的起始點,反映 8.9% 至 10.4% 的成長。其中包含相較於 Waters 單獨基礎的調整後 EPS、來自本次交易的 0.10 美元增厚(accretion),即使尚未達到完整年度持有期亦然。接下來,我將把電話會議交給 Amol,由他檢視財務狀況並更詳細說明我們的指引。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Thank you, Udit, and good morning, everyone. In the fourth quarter, we delivered a strong finish to the year with as reported sales and adjusted EPS landing at the high end of our guidance. Sales of $932 million grew 7% as reported and 6% in constant currency. Orders growth outpaced sales growth in the quarter. By end market, pharma grew 7%.

    謝謝你,Udit,各位早安。在第四季,我們以強勁表現為今年畫下句點;按報告口徑的銷售額與調整後每股盈餘(adjusted EPS)皆落在我們指引區間的高端。銷售額為9.32億美元,按報告口徑成長7%,按固定匯率成長6%。本季訂單成長快於銷售成長。按終端市場來看,製藥成長7%。

  • Industrial grew 8%, while academic and government declined 3%. In Pharma, growth was led by mid-teens performance in Asia, high single-digit growth in Europe and low single-digit growth in Americas. Instrument replacement remains strong along with new product adoption in both our instrument and chemistry portfolios.

    工業成長8%,而學術與政府下滑3%。在製藥領域,成長主要由亞洲中十位數(mid-teens)的表現帶動,歐洲高個位數成長,美洲低個位數成長。儀器汰換需求依然強勁,同時我們的儀器與化學產品組合中新產品導入也持續推進。

  • In Industrial, Waters division grew low teens with double-digit strength across chemical analysis, food and environmental testing. Performance was supported by continued momentum in PFAS-related workflows, led by the sensitivity and robustness of the Xevo TQ Absolute XR mass spec system.

    在工業領域,Waters 事業部成長低十位數(low teens),在化學分析、食品與環境檢測等領域皆呈現雙位數的強勁成長。表現受惠於與 PFAS 相關工作流程的持續動能,主要由 Xevo TQ Absolute XR 質譜系統的高靈敏度與高穩健性所帶動。

  • TA division was flat, reflecting an improvement versus the first half of the year as customer spending trends continue to recover. In academic and government, strong double-digit growth in Americas was offset by year-over-year spending declines in other regions.

    TA 事業部持平,反映相較於上半年有所改善,因客戶支出趨勢持續復甦。在學術與政府領域,美洲強勁的雙位數成長被其他地區年對年支出下滑所抵銷。

  • By region, Asia grew low double digits, while Americas and Europe grew mid-single digits. Within Asia, India grew high teens, reflecting continued strength in pharma generics. In China, sales grew 3% as strength in pharma and industrial was partially offset by timing of stimulus-related funding in academic and government.

    按地區來看,亞洲成長低雙位數,而美洲與歐洲成長中個位數。在亞洲內部,印度成長高十位數(high teens),反映學名藥製藥領域持續強勁。在中國,銷售成長3%;製藥與工業的強勢表現,部分被學術與政府刺激相關資金到位時點所抵銷。

  • By product line, instrument sales grew 3%. High single-digit LC-MS growth was partially offset by a low single-digit decline in TA system sales. We also incurred a low single-digit percentage growth impact from successful customer migration to Empower subscription agreements, which carry long-term recurring revenue benefits.

    按產品線來看,儀器銷售成長3%。LC-MS 高個位數成長,部分被 TA 系統銷售低個位數下滑所抵銷。此外,因客戶成功轉移至 Empower 訂閱合約(可帶來長期經常性收入效益),我們也因此產生低個位數百分比的成長貢獻。

  • Recurring revenues grew 9%, driven by 8% growth in service and 12% growth in chemistry. We again saw fantastic customer adoption of our bioseparation columns which have been a vertical success in the market.

    經常性收入成長9%,主要由服務成長8%與化學品成長12%所帶動。我們再次看到客戶對生物分離色譜柱的極佳採用度,該產品已在市場上成為垂直領域的成功案例。

  • Adjusted earnings per share grew 10% to $4.53, GAAP earnings per share were $3.77. For the full year, sales grew 7% on both a reported and constant currency basis. By end market, pharma grew 9%. Industrial grew 6%, while academic and government declined 1%. In pharma, all regions delivered high single-digit growth or better, led by Asia, which grew low double digits.

    調整後每股盈餘成長10%至4.53美元,GAAP 每股盈餘為3.77美元。全年來看,銷售額按報告口徑與固定匯率口徑皆成長7%。按終端市場來看,製藥成長9%。工業成長6%,而學術與政府下滑1%。在製藥領域,各地區皆達到高個位數或更佳的成長,其中以亞洲領先,成長低雙位數。

  • In Industrial, Waters division grew low double digits with broad-based double-digit strength across chemical analysis, food and environmental testing. This was partially offset by a 1% decline in TA division. In academic and government, the Americas and China grew mid-single digits, while Europe declined 5%. By region, Asia grew low teens while Americas and Europe grew mid-single digits. Within Asia, India grew high teens and China grew 9%.

    在工業領域,Waters 事業部成長低雙位數,在化學分析、食品與環境檢測等領域皆呈現廣泛的雙位數強勁成長。這部分被 TA 事業部下滑1%所部分抵銷。在學術與政府領域,美洲與中國成長中個位數,而歐洲下滑5%。按地區來看,亞洲成長低十位數(low teens),美洲與歐洲成長中個位數。在亞洲內部,印度成長高十位數,中國成長9%。

  • Our strength in China was driven by broad-based growth across pharma, industrial and A&G. This was supported by share gains in biotech and CDMOs, chemical and environmental workflows and A&G. By product line, instrument sales grew 5%, led by high single-digit LC-MS growth. Recurring revenues grew 8% with 7% service growth and 12% chemistry growth. For the full year, adjusted earnings per share grew 11% to $13.13.

    我們在中國的強勢表現,來自製藥、工業與學術與政府(A&G)等領域的廣泛成長。這也受惠於我們在生技與 CDMO、化學與環境工作流程以及 A&G 領域的市占提升。按產品線來看,儀器銷售成長5%,主要由 LC-MS 高個位數成長帶動。經常性收入成長8%,其中服務成長7%、化學品成長12%。全年調整後每股盈餘成長11%至13.13美元。

  • On a GAAP basis, EPS was $10.76. Within the P&L, gross margin was 61.1% for the quarter and 59.3% for the full year, which was better than expected. Adjusted operating margin was 35.2% for the quarter and 30.5% for the year. This reflects the deliberate acceleration of strategic R&D investments in chemistry and informatics, along with the impact of regional sales mix and tariff surcharges. Our operating tax rate came in at 15.7% for both the quarter and the year.

    按 GAAP 口徑,每股盈餘為10.76美元。在損益表方面,本季毛利率為61.1%,全年為59.3%,優於預期。調整後營業利益率本季為35.2%,全年為30.5%。這反映我們有意加速在化學與資訊學(informatics)方面的策略性研發投資,以及地區銷售組合與關稅附加費的影響。我們的營運稅率在本季與全年皆為15.7%。

  • The full year rate includes approximately 50 basis points of discrete benefit related to a change in US tax legislation enacted in 2025. Turning to cash generation and the balance sheet. Free cash flow was $125 million in the quarter after funding $39 million of capital expenditures, and $15 million of transaction-related costs.

    全年稅率包含約50個基點的一次性利益,與2025年通過的美國稅法變更相關。接著談現金創造與資產負債表。本季自由現金流為1.25億美元,係在投入3,900萬美元資本支出,以及1,500萬美元交易相關成本之後的結果。

  • For the full year, free cash flow totaled $677 million, after funding $113 million of capital expenditures, inclusive of tariff-related mitigation actions and $29 million of transaction-related costs.

    全年自由現金流合計為6.77億美元,係在投入1.13億美元資本支出(包含關稅相關的緩解措施)以及2,900萬美元交易相關成本之後的結果。

  • Our net debt position at the end of the year was $820 million. Now I will share further commentary on our 2026 outlook and provide our first quarter guidance. We are executing well with a revitalized portfolio leveraging instrument replacement and benefiting from our idiosyncratic growth drivers.

    年底的淨負債為8.20億美元。接下來我將進一步說明我們對2026年的展望,並提供第一季指引。我們執行表現良好,透過儀器汰換帶動並受惠於我們特有的成長驅動因素,讓產品組合重獲活力。

  • We expect this momentum to continue into 2026. As a prudent starting point, these dynamics support stand-alone full year 2026 organic constant currency revenue growth of 5.5% to 7%.

    我們預期這股動能將延續至2026年。作為審慎的起點,這些動態支持我們在不含併購的前提下,2026年全年有機固定匯率營收成長5.5%至7%。

  • We expect favorable foreign exchange translation to provide 0.5% tailwind to organic sales, which translates to organic reported revenue of $3.355 billion to $3.405 billion in 2026. Turning to the acquired business contribution, following today's expected closing of the transaction, we expect the acquired Biosciences and Diagnostic Solutions businesses to contribute $3 billion of revenue in 2026.

    我們預期有利的外匯換算將為有機銷售帶來0.5%的順風,對應到2026年有機按報告口徑營收為33.55億至34.05億美元。再看併購業務的貢獻,隨著今日預期完成交易交割,我們預期收購的 Biosciences 與 Diagnostic Solutions 業務在2026年將貢獻30億美元營收。

  • In setting this expectation, we have risk-adjusted the underlying growth assumptions, even though most of the headwinds that impacted the business in 2025 are already in the baseline as we enter 2026.

    在設定此一預期時,我們已對基礎成長假設進行風險調整,儘管2025年影響該業務的大部分逆風,在進入2026年時已反映在基準之中。

  • Our guidance prudently assumes approximately 2.5% underlying constant currency growth for these businesses in 2026 on an owned period basis before any benefit from execution and pricing improvements or our organizational changes.

    我們的指引審慎假設,這些業務在2026年以持有期間(owned period)計算、且尚未納入執行與定價改善或組織調整帶來的任何效益之前,其固定匯率的基礎成長約為2.5%。

  • In addition, we expect to realize approximately $50 million of revenue synergies in 2026, reflecting the initial contribution from the first wave of commercial excellence initiatives discussed earlier.

    此外,我們預期在2026年實現約5,000萬美元的營收綜效,反映先前所述第一波商業卓越(commercial excellence)計畫的初步貢獻。

  • Taken together, this results in a total reported 2026 revenue of $6.405 billion to $6.455 billion. These starting consumptions imply blended year-over-year constant currency growth of approximately 5.3% for the combined company in 2026.

    綜合以上,2026年按報告口徑的總營收將為64.05億至64.55億美元。這些起始假設意味著,合併後公司在2026年的年對年固定匯率混合成長約為5.3%。

  • From a profitability perspective, we expect to deliver an adjusted EBIT margin of 28.1% in 2026, consistent with our deal model. This reflects approximately 80 basis points of adjusted operating margin expansion at Waters on a stand-alone basis, consistent with our Investor Day algorithm to approximately 31.3%.

    從獲利能力角度來看,我們預期2026年可達成調整後 EBIT 利潤率28.1%,與我們的交易模型一致。這反映 Waters 在不含併購的前提下,調整後營業利益率約擴張80個基點,符合我們投資人日(Investor Day)的演算法,提升至約31.3%。

  • An adjusted operating margin percentage of approximately 22.4% for Biosciences and Diagnostic Solutions, a $25 million contribution from the $50 million anticipated revenue synergies, and $55 million contribution from anticipated cost synergies.

    Biosciences 與 Diagnostic Solutions 的調整後營業利益率約為22.4%,其中包含預期5,000萬美元營收綜效所帶來的2,500萬美元貢獻,以及預期成本綜效所帶來的5,500萬美元貢獻。

  • Below the line, net interest expense is expected to be approximately $179 million and our full year tax rate is expected to be approximately 16.6%. From a share count perspective, our updated capital structure results in approximately 94.3 million diluted shares outstanding on a full year average basis in 2026.

    在稅前項目以下,淨利息費用預計約為1.79億美元,而我們全年稅率預計約為16.6%。從股數角度來看,我們更新後的資本結構使得2026年全年平均基礎下的稀釋流通股數約為9,430萬股。

  • At closing, our new share count is 98.4 million shares. This translates to full year 2026 adjusted earnings per fully diluted share of $14.30 to $14.50 and represents 8.9% to 10.4% growth. It includes $0.10 of adjusted EPS accretion versus Water stand-alone non-GAAP EPS profile due to the transaction already before a first full year of ownership.

    在交割時,我們新的股數為9,840萬股。這相當於2026年全年每股完全稀釋後調整後盈餘為14.30至14.50美元,並代表8.9%至10.4%的成長。其中包含因交易在尚未滿第一個完整持有年度前即已發生,使得相較於Water獨立口徑的非GAAP每股盈餘(EPS)概況,調整後EPS增加0.10美元。

  • It is important to note that quarterly EPS figures are not additive to the full year EPS due to a significant change in average shares outstanding between the first quarter and the remainder of the year. For the first quarter of 2026, we are beginning the year with strong momentum across our core businesses.

    需要特別注意的是,由於第一季與今年其餘期間的平均流通股數出現顯著變化,各季EPS數字無法加總為全年EPS。對於2026年第一季,我們以核心業務全面強勁的動能展開新的一年。

  • We expect stand-alone organic constant currency revenue growth of 7% to 9%. With tailwinds from favorable foreign exchange translation, the reported stand-alone revenue is expected to be approximately $718 million to $731 million.

    我們預期獨立口徑的有機、固定匯率營收成長為7%至9%。在有利的外匯換算帶動下,申報的獨立口徑營收預計約為7.18億至7.31億美元。

  • Turning to the acquired business contribution we expect the Biosciences and Diagnostic Solutions businesses to contribute $480 million of revenue in the partial first quarter of 2026. This calls for a low single-digit revenue decline. Quarterly rate trends reinforce our confidence in this outlook.

    接著看併購業務的貢獻,我們預期生物科學(Biosciences)與診斷解決方案(Diagnostic Solutions)業務在2026年第一季(部分季度)貢獻4.80億美元營收。這意味著營收將出現低個位數的下滑。季度化的趨勢進一步強化我們對此展望的信心。

  • Taken together, this results in a total reported first quarter 2026 revenue of $1.198 billion to $1.211 billion. For modeling purposes, first quarter average share count is expected to be $82 million and tax rate is expected to be consistent with our full year outlook.

    綜合以上,2026年第一季申報的總營收將為11.98億至12.11億美元。就建模而言,第一季平均股數預計為8,200萬股,稅率預計與我們全年展望一致。

  • While the transaction is expected to be EPS accretive for the full year 2026, the first quarter will reflect the full burden of interest expense and the higher share count, with synergies beginning to ramp up in subsequent quarters. As a result, the first quarter adjusted earnings per fully diluted share is expected to be in the range of $2.25 to $2.35, which is flat to 4.4% growth. Embedded within this guide is stand-alone EPS of $2.50, or 10% growth versus prior year at midpoint. With that, I will now hand the call back to Udit.

    雖然此交易預期在2026年全年將對EPS具增益(accretive),但第一季將反映利息費用的全額負擔以及較高的股數,而協同效益將在後續季度開始逐步放大。因此,第一季每股完全稀釋後調整後盈餘預計介於2.25至2.35美元,約為持平至成長4.4%。此指引中隱含的獨立口徑EPS為2.50美元,以中位數計較去年成長10%。接下來我把電話交回給Udit。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Thank you, Amol. So to summarize, with a revitalized core portfolio expanded high-growth adjacencies and tangible synergy levers now underway we are entering 2026 with strong momentum and a highly compelling growth outlook.

    謝謝你,Amol。總結來說,隨著核心產品組合煥然一新、高成長相鄰領域擴張,以及可落地的協同槓桿已開始推進,我們正以強勁動能與極具吸引力的成長前景邁入2026年。

  • Our growth outlook of 5.3% at midpoint for the combined company is appropriately prudent, yet industry-leading even before factoring in the full benefits of upcoming execution improvements, which we will now work decisively to implement. Within the P&L, we are confident in our ability to accelerate value creation as the year progresses. We look forward to updating you on our progress as we move through the year.

    合併公司在指引中位數5.3%的成長展望是適度審慎的,但即使尚未納入即將到來的執行改善所帶來的完整效益,仍屬產業領先;我們將果斷推動落實。在損益表(P&L)層面,隨著年度推進,我們對加速價值創造的能力充滿信心。我們期待在今年進行過程中向各位更新我們的進展。

  • So with that, I will now turn the call back to Caspar.

    那麼,我現在把電話交回給Caspar。

  • Caspar Tudor - Head of Investor Relations

    Caspar Tudor - Head of Investor Relations

  • Thanks, Udit. That concludes our prepared remarks. We are now happy to open the lines and take your questions.

    謝謝,Udit。以上為我們的事先準備發言。我們現在很高興開放線路並回答各位的提問。

  • Operator

    Operator

  • (Operator Instructions).

    (接線員指示)。

  • Tycho Peterson, Jefferies.

    Tycho Peterson,Jefferies。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Hey, thanks. Udit, I think the two things people really want to dig into here are obviously the BD results this morning and the numbers, obviously, have deteriorated relative to the original deal model. So maybe just talk a little bit about your take on the numbers this morning, particularly for the lagging parts of the portfolio, US academic government, China, early-stage research on the BD side. And how do we think about the path to recovery there?

    嗨,謝謝。Udit,我想大家最想深入了解的兩件事,顯然是今天早上BD的業績以及相關數字;很明顯,相較於原始交易模型,表現已經惡化。所以也許請你談談你對今天早上這些數字的看法,特別是投資組合中落後的部分:美國學術/政府、中國,以及BD端的早期研究。我們該如何看待那邊的復甦路徑?

  • And then the second thing is instruments, right? And the Empower impact on that transition. I understand it's, call it, 250 basis point headwind this quarter. But how do we think about the go-forward P&L impact on instruments from this Empower transition?

    第二件事是儀器(instruments),對吧?以及Empower對那個轉換的影響。我理解本季大約是250個基點的逆風。但我們該如何看待這次Empower轉換對儀器業務未來損益表(P&L)的影響?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • So Tycho, thanks for the two questions. So let me start with the BD Diagnostic Solutions and Bioscience business first. Look, several issues emerged in Q4 that impacted the growth of both of those businesses that were not fully known in Q3.

    Tycho,謝謝這兩個問題。我先從BD的診斷解決方案與生物科學業務談起。你看,第四季出現了幾個問題,影響了這兩項業務的成長,而這些在第三季時並未完全掌握。

  • And I'll let Amol describe those in a few minutes. But what is important is that all of these will now be present in a lower baseline for us in 2026 to basically help us deliver the 2.5%, which we think has several upsides.

    我會讓Amol在幾分鐘後說明這些問題。但重要的是,這些因素在2026年將反映在較低的基期上,基本上有助於我們達成2.5%的成長,我們認為其中還有多項上行空間。

  • Now this reminds me of Waters almost five years ago, right? You couple this with a host of innovative new products in both diagnostic solutions and in Bioscience across flow cytometry, as well as across the microbiology business and the molecular diagnostics business.

    這讓我想起大約五年前的Waters,對吧?再加上診斷解決方案與生物科學兩邊都有一系列創新新品,涵蓋流式細胞儀(flow cytometry),以及微生物(microbiology)與分子診斷(molecular diagnostics)業務。

  • You start at a fresh portfolio. And -- so we are now really squarely focused on, first, improving the operational execution, for instance, by implementing a deal desk for pricing discipline and discounting discipline, ensuring launch readiness of this fantastic portfolio, just like we did with Alliance iS and improving forecast accuracy to minimize surprises. And equally, after months of detailed integration planning, we're now ready to deliver the synergies.

    你是從一個全新的產品組合出發。因此——我們現在非常聚焦於:第一,改善營運執行,例如導入deal desk以強化定價紀律與折扣紀律,確保這個出色產品組合的上市準備就緒(launch readiness),就像我們在Alliance iS上所做的一樣,並提升預測準確度以將意外降到最低。同樣重要的是,經過數月的詳細整合規劃,我們現在已準備好交付協同效益。

  • Be it around instrument replacement, e-commerce or service attach. And look, I mean, the service attach was starting at a 40% number. And you've seen what we've already done in 2025 alone. So we're very confident to deliver the $50 million in revenue synergies and more. You add this to what a stand-alone guidance is and you end up with over 5%, close to 5.3% in at the midpoint of the guide for the combined business.

    不論是在儀器汰換(instrument replacement)、電商(e-commerce)或服務綁定率(service attach)方面。而且你看,服務綁定率一開始只有40%。你也看到我們光是在2025年就已經做了哪些改善。因此我們非常有信心達成5,000萬美元的營收協同效益,甚至更多。把這些加到獨立口徑指引上,你就會得到合併後業務在指引中位數超過5%、接近5.3%的成長。

  • So we're feeling pretty good about that industry-leading growth rate as we head into 2026. Amol, do you want to comment on the dynamics of the two businesses in 2025?

    因此,在邁入2026年之際,我們對這個產業領先的成長率感到相當樂觀。Amol,你要不要評論一下2025年這兩項業務的動態?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah, Yes. I mean, look, coming into the fourth quarter, we were starting to see the DRG headwind in China. And then we knew Q4 had a higher baseline from the prior year IP onetime revenue, right? But then a couple of other things sort of crept in, which is a weaker flu season, coupled with challenges getting exemptions on shipments to China because of the government shutdown.

    好,當然。我的意思是,你看,進入第四季時,我們開始看到中國DRG帶來的逆風。而且我們知道第四季的基期較高,因為去年有一次性的IP收入,對吧?但另外還有幾件事也逐漸浮現:流感季較弱,再加上因政府停擺,對中國出貨在取得豁免方面遇到挑戰。

  • Now as we get into Q1, three out of the four are sort of behind us in terms of the baseline for the flu season, no IP issues in the baseline for the first quarter as well as, remember, the China export ban started at the beginning of the first quarter last year.

    現在進入第一季,四項因素中有三項在基期上已經算是過去了:包括流感季的基期、第一季基期中也沒有IP問題;另外也請記得,對中國的出口禁令是從去年第一季一開始就啟動的。

  • So from a baseline point of view, it's pretty clean, except for the DRG issue, which will start to come in the baseline late Q3. And quarter-to-date trends give us a lot of confidence that where we are guiding, which is a low single-digit decline for Q1 is sort of a reasonable guide.

    因此,從基準的角度來看,整體相當乾淨,除了 DRG 的問題之外;該影響將在第三季末開始納入基準。而截至目前的季度趨勢讓我們非常有信心:我們所給出的指引——第一季為低個位數下滑——算是一個合理的參考。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • So now turning to your second question on instruments. Really happy with instruments performance. LC-MS grew high single digits again. And this is like through the year, every quarter has been high single digits to double digits for LC-MS with the same drivers, instrument replacement cycle still going strong, as well as the idiosyncratic growth drivers plus the new products.

    接著談您第二個關於儀器的問題。我們對儀器的表現非常滿意。LC-MS 再次實現高個位數成長。而且這就像過去一年一樣,LC-MS 每一季都維持高個位數到雙位數成長,驅動因素相同:儀器汰換週期仍然強勁,再加上特定的成長驅動因素以及新產品。

  • TA was a drag at a low single-digit percentage to the overall instrument number given the weakness in both the US and Europe. And -- what's great news is something that we've been telegraphing for a while is the transition of Empower from on-prem to subscription where several large pharma customers transitioned in Q4, and that was about a low single-digit headwind to the overall instrument number.

    由於美國與歐洲雙雙疲弱,TA 對整體儀器數字造成低個位數百分比的拖累。另外——好消息是,我們已經預告一段時間的 Empower 從地端部署(on-prem)轉向訂閱制;第四季有數家大型製藥客戶完成轉換,這對整體儀器數字帶來約低個位數的逆風。

  • So overall, LC-MS high single-digit growth. TA was a low single-digit percentage headwind just given the challenges in US and Europe.

    因此整體而言,LC-MS 高個位數成長。TA 因美國與歐洲的挑戰,帶來低個位數百分比的逆風。

  • And Empower really a wonderful transition that we told you that we will talk about it. We will talk about it in the rearview mirror. Now as you look ahead into 2026, Q1 started off extremely well on the instrument side. The funnel is extremely strong. Orders grew faster than sales in Q4.

    而 Empower 的轉型確實非常出色,我們也告訴各位我們會談這件事。我們會在事後回顧時再談。現在展望 2026 年,第一季在儀器端開局非常好。商機漏斗非常強勁。第四季訂單成長快於銷售成長。

  • So we feel very good about where we're starting. And the guide we have given for Q1 and the full year. And all the drivers are currently fully intact. And we've also accounted in the guidance that we've given for the Empower headwinds that we expect during the year as customers transition from the CapEx to a recurring revenue model. So all going according to plan and really happy with, especially the Empower transition that

    所以我們對起步狀況感到非常好。以及我們對第一季與全年所給出的指引。所有驅動因素目前都完全健在。而且我們也已在指引中納入我們預期全年會出現的 Empower 逆風,因為客戶將從資本支出(CapEx)模式轉向經常性收入模式。因此一切按計畫進行,我們也非常滿意,尤其是 Empower 的轉型,這

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • And it's a fantastic problem to have, right? Two of the top 5 pharma's converted. And I mean, Q1 funnel is strong, so we're not less.

    而且這是一個很棒的問題要有,對吧?前五大製藥公司中有兩家已完成轉換。而且我的意思是,第一季漏斗很強,所以我們不會更少。

  • Operator

    Operator

  • Catherine Schulte, Baird.

    Catherine Schulte,Baird。

  • Catherine Schulte - Analyst

    Catherine Schulte - Analyst

  • Maybe first, just for the full year guide of 5.5% to 7% after starting at 7% to 9% in the first quarter (inaudible) some deceleration for the balance of the year. Is that just prudence to start the year? Is it comp driven? Or are there some other dynamics we should be aware of?

    也許先問一下,全年指引為 5.5% 到 7%,而第一季一開始是 7% 到 9%(聽不清),這意味著今年其餘時間會有一些放緩。這只是年初保守起見嗎?是因為比較基期(comp)因素驅動嗎?還是有其他我們需要注意的動態?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • So first on the full year guide, the 5.5% to 7%, Catherine. Look, our guidance philosophy has generally not changed, right? I mean, the lower end of the guide constitutes where we think instruments are going to end up and I'd given a lot of detail to Tycho's question on that front already.

    先談全年指引 5.5% 到 7%,Catherine。你看,我們的指引哲學基本上沒有改變,對吧?我的意思是,指引下緣反映我們認為儀器最終會落在的水準,而我在回答 Tycho 的問題時已就此提供了很多細節。

  • So we feel very good about where we're starting on the instrument side at 5.5%. And on the 7% at the top end of the guide, that is our recurring revenue, sort of, guidance for the year.

    因此,我們對儀器端以 5.5% 起步的狀況感到非常好。而指引上緣 7%,那是我們對全年經常性收入的某種指引。

  • This basically again constitutes several upsides that we've not baked into the guide itself. I mean we've assumed that the academic and government drug discovery from our research segments don't recover. In China, we've assumed a mid-single-digit growth versus what we've done this year, which is about 9%.

    這基本上再次包含了幾個我們尚未納入指引本身的上行空間。我的意思是,我們假設研究部門中的學術與政府藥物發現不會復甦。在中國,我們假設為中個位數成長,相較於今年約 9% 的表現。

  • I mean, a fantastic growth in China, but we've assumed mid-single-digit and not included any sort of stimulus revenue. We've incorporated already the Empower headwinds from converting from CapEx to a recurring revenue.

    我的意思是,中國成長非常亮眼,但我們假設的是中個位數,且未納入任何刺激方案帶來的收入。我們已經把 Empower 從資本支出(CapEx)轉為經常性收入所帶來的逆風納入。

  • This does not include reshoring revenues. And finally, for the full year, we've assumed that chemistry is roughly 6% in our guide, while finishing the year at 12% in chemistry growth rates. So several areas to basically have risk on the upside. And so I feel pretty good about where we're starting with the guide. On Q1, Amol, do you want to talk about the 7% to 9%?

    這不包含回流生產(reshoring)收入。最後,就全年而言,我們在指引中假設化學業務約為 6%,而今年化學業務的成長率收在 12%。因此有幾個領域基本上存在上行風險。所以我對目前這個指引的起點感覺相當不錯。至於第一季,Amol,你要不要談一下 7% 到 9%?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah, I mean in general, the momentum coming into Q1 is really strong, and that coupled with four extra working days sort of supports our guide. And that then sort of derisks the remainder of the year.

    是的,整體而言,進入第一季的動能非常強,再加上多了四個工作天,這些都支撐了我們的指引。而這也在某種程度上降低了今年其餘時間的不確定性。

  • Catherine Schulte - Analyst

    Catherine Schulte - Analyst

  • Okay. Got it. And apologies if I missed it in your response to Tycho's question. But on -- for the outlook for the BD assets, any comment on pacing there? And maybe what we should expect from a fourth quarter exit rate for BD on the path to recovery?

    好的。了解。如果我在你回覆 Tycho 的問題時漏聽了,先說聲抱歉。但關於 BD 資產的展望,能否評論一下節奏?以及在走向復甦的路徑上,我們對 BD 第四季的退出(exit)成長率應該有什麼期待?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah. I mean, look, we expect sort of a low single-digit decline in Q1 and then growth sort of gradually starting to ramp up. as we go through the remainder of the year as some of the headwind gets more and more rooted in the baseline, particularly as we enter Q3 and Q4 when the DRG headwind is in the baseline.

    是的。我的意思是,我們預期第一季會是低個位數下滑,之後隨著今年其餘時間推進,成長會逐步開始加速爬升;因為部分逆風會越來越被納入基準之中,特別是進入第三季與第四季時,DRG 逆風會在基準裡。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yeah, and Catherine, look, equally, you should know that we are squarely focused on improving the operational execution. And as I mentioned before, this is around ensuring that there is a forecast accuracy in the business. There is a pricing discipline, not just on setting the price but also on discounting, which impacts both the top and the bottom line, and we've done that successfully at Waters.

    是的,而且 Catherine,你也應該知道,我們正全力聚焦於提升營運執行。如我先前提到的,這包括確保業務的預測準確度。也包括價格紀律——不僅是訂價,還包括折扣管理;折扣會同時影響營收與獲利,而我們在 Waters 已成功做到這點。

  • And also ensuring that the launches for the new products that are coming through go extremely well and something we've done by targeting segmenting very precisely for our Alliance iS and TQ Absolute products.

    同時也要確保即將推出的新產品能夠非常順利地上市;我們透過對 Alliance iS 與 TQ Absolute 產品進行非常精準的目標鎖定與市場區隔來做到這點。

  • And equally, we're squarely focused on taking all the work that's happened in integration planning, and implementing that throughout the year to increase momentum on the revenue synergy side. Instrument replacement service attach and e-commerce should contribute immediately. So feel very good about the starting point after a lot of planning.

    同樣地,我們也全力聚焦於把整合規劃階段所完成的所有工作,在全年落地執行,以提升營收協同的動能。儀器汰換的服務綁定(service attach)與電子商務應會立即帶來貢獻。因此在大量規劃之後,我們對起步點感到非常好。

  • Operator

    Operator

  • Jack Meehan, Nephron.

    Jack Meehan,Nephron。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • Udit, on BD, you talked a couple of times about setting up a deal desk for pricing. Can you talk about which product areas are in focus and how you think -- how you think that's been optimized in the past?

    Udit,關於 BD,你提到好幾次要建立一個用於訂價的 deal desk。你能談談目前聚焦哪些產品領域,以及你認為——你認為過去這在優化上是怎麼做的嗎?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yeah. So look, I mean, almost five years ago, we set up the same process at Waters, and it has two, maybe three parts. The first is a centralized examination of what the list is prices are, as well as what the discounting is, and that escalates all the way up to me as discounting requests come from the different regions.

    可以。你看,大約五年前,我們在 Waters 建立了同樣的流程,它包含兩個,也許三個部分。第一個是集中式檢視牌價(list prices)以及折扣情況;當各地區提出折扣申請時,會一路升級到我這裡來審核。

  • So we've -- basically, we take away the ability for regions and sales teams to discount. So any time there's a list price increase, the stick rate is much higher.

    所以我們——基本上,我們取消了各區域與銷售團隊打折的權限。因此每當名目表價上調時,價格落地(stick rate)就會高得多。

  • This is especially relevant for products in the instrument category. Now here, you have a couple of new products that have been launched across the Biosciences and diagnostics businesses. The most of all being the fax discover line S8, A8 as well as S7, A7 that are coming up.

    這對儀器類別的產品尤其相關。在這裡,你們在生命科學與診斷業務中推出了幾款新產品。其中最重要的是 FACSDDiscover 產品線的 S8、A8,以及即將推出的 S7、A7。

  • And for instruments, it's extremely important to not sort of lose the pricing discipline as you negotiate the deals, it's pretty easy to sort of give away pricing on highly innovative products, if you're not disciplined. And on the recurring revenue side, we see a benefit both on the service piece so that we are charging for installation.

    對於儀器而言,在談判交易時維持定價紀律極其重要;如果不夠自律,對高度創新的產品很容易就把價格讓出去。而在經常性收入方面,我們在服務端也看到好處,例如我們會對安裝收費。

  • We're charging for spare parts in an appropriate way, but also on the reagent side, where there is no reason for BD to not command the same sort of price premium that our chemistry revenue does. These are highly differentiated dies and antibodies that only BD producers, and these are of the highest quality.

    我們也會以適當方式對備品備件收費;同時在試劑端亦然,BD 完全沒有理由不能取得與我們化學業務收入相同水準的價格溢價。這些是高度差異化的染料與抗體,只有 BD 生產,而且品質是最高等級。

  • So there is zero reason why there should be discounting there. So we expect those to immediately impact and those impact both the top line and the bottom line, Jack.

    所以那裡完全沒有任何折扣的理由。因此我們預期這些會立即產生影響,而且這些影響同時反映在營收端與獲利端,Jack。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • Great. And then for Amol, can you give us an update on the pro forma leverage for Waters and how you expect that to evolve over the year? And kind of similarly, what is the guide for interest expense assumed for any refinancing? thank you.

    很好。接著問 Amol,你能否更新一下 Waters 的備考槓桿(pro forma leverage)狀況,以及你預期它在今年內會如何演變?另外類似地,利息費用的指引是什麼?是否假設會有任何再融資?謝謝。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah. So I mean, look, we will be roughly at a net debt of somewhere around $4.6 billion, $4.7 billion, right? And that would translate to roughly around 2.4 times net debt to EBITDA, slightly more than what we announced because the deal closed earlier than what we had anticipated, which is great.

    好的。所以我的意思是,你看,我們的淨負債大約會在 46 億到 47 億美元左右,對吧?換算下來,淨負債對 EBITDA 大約是 2.4 倍,會比我們先前公告的略高一些,因為交易比我們預期更早完成,這其實是好事。

  • And then we expect to be below 2 times within sort of 18 months time frame. And then interest expense on a pro forma basis is about $179 million for 2026.

    然後我們預期在大約 18 個月的時間框架內降到 2 倍以下。另外,以備考口徑計算,2026 年的利息費用大約是 1.79 億美元。

  • Operator

    Operator

  • Doug Schenkel, Wolfe.

    Doug Schenkel,Wolfe。

  • Doug Schenkel - Equity Analyst

    Doug Schenkel - Equity Analyst

  • Good morning, I actually just have one topic I'd like to cover, just on the synergy targets. I think your initial year one guidance assumes you cut 5% to 6% of the acquired businesses OpEx, assuming I have that math, right? So I guess one question would be, do I have that math right? And if so recognizing this is on day one, and I think it's about twice what you previously outlined. What's driving this increase?

    早安,我其實只有一個主題想談,就是協同效益目標。我認為你們最初對第一年的指引,假設會削減被收購業務 5% 到 6% 的營業費用(OpEx),如果我這樣算沒錯的話。所以我想問的第一個問題是:我這樣算對嗎?如果是的話,考量這是第一天(day one),而且我覺得這大概是你們之前提到的兩倍。是什麼因素推動了這個增加?

  • And recognizing this is a pretty big number to start, I'm just wondering how you're thinking about potential upside to that year one target, given what seems to be strong momentum in identifying opportunities in the early going? thank you.

    另外也考量這一開始就是個相當大的數字,我想了解你們如何看待第一年目標可能的上行空間,因為看起來在早期辨識機會方面的動能很強?謝謝。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Hi, Doug. So look, I mean, our underwriting model assumed roughly 4% -- 4%, 4.5% of the pro forma cost base of Waters stand-alone plus the acquired business. And that had certain elements baked into it, like site consolidations, like sort of commercial and technology. And also, it did not include certain elements in the underwriting. When you compare and contrast it versus deals of this size, you typically see sort of 6% number.

    嗨,Doug。你看,我們的承銷模型(underwriting model)假設大約是備考成本基礎的 4%——4% 到 4.5%,也就是 Waters 單獨(stand-alone)加上被收購業務的合併口徑。其中已經內含一些要素,例如據點整併,以及商業與技術相關的項目。同時,在承銷時也沒有把某些要素納入。如果你拿它和同等規模的交易相比,通常會看到大約 6% 的數字。

  • What Udit and [chris ross] achieved at Sigma Millipore was more like 8% number. We haven't baked in that level of targets in our underwriting because, one, we want to give ourselves some space. And we to -- for a deal of this size, there's always skeletons that you find and gives this room to cover for that.

    Udit 和 [chris ross] 在 Sigma Millipore 達成的更接近 8%。我們沒有在承銷中納入那樣水準的目標,原因之一是我們希望給自己留一些空間。而且——對於這種規模的交易,你總會發現一些「骨架」(意外問題),留出空間也能用來吸收這些狀況。

  • If you now look at our guide, we're pretty much on track to deliver exactly what we said in our deal announcement. And we feel really good that after having done a lot of work over the last several months we are well on track to deliver our deal announcement commitments.

    如果你現在看我們的指引,我們基本上正按計畫交付我們在交易公告時所說的內容。而且我們非常有信心:在過去幾個月做了大量工作之後,我們完全在軌道上,能夠達成交易公告時承諾的事項。

  • Operator

    Operator

  • Matt Larew, William Blair.

    Matt Larew,William Blair。

  • Matt Larew - Analyst

    Matt Larew - Analyst

  • Hi, good morning. Sticking with BD, maybe thinking about the revenue synergy side, the results from the most recent quarter called out a number of issues, but maybe even over the last couple of years, might be suggestive of a business in need of commercial investment to improve execution.

    嗨,早安。延續 BD 的話題,從營收協同的角度來看,最近一季的結果提到了一些問題;但甚至回看過去幾年,可能都暗示這是一個需要商業端投資、以改善執行力的業務。

  • How do you think about the level of investment needed for the business long term, and how that perhaps works with the idea of the EBIT contribution you're hoping to get from revenue synergies?

    你們如何看待這項業務長期所需的投資水準?以及這可能如何與你們希望從營收協同中取得的 EBIT 貢獻相互配合?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • So Matt, that's a really good question and something that we invested a lot of time in doing the integration planning. Now you take -- you take what I mentioned on the pricing discipline or launch readiness. We have central teams that we will now deploy into the businesses -- into the acquired businesses to implement this pricing discipline and train the teams locally and eventually leave a few of these people behind to manage that on a day-to-day basis.

    Matt,這是個非常好的問題,也是我們在整合規劃上投入大量時間的議題。你把——把我剛才提到的定價紀律或上市準備度(launch readiness)放在一起看。我們有中央團隊,接下來會派駐到各業務——到被收購的業務中,去落實這套定價紀律、在當地訓練團隊,並最終留下其中一些人,負責日常管理。

  • Something we've done in the past as well. So the pricing discipline that we've seen at Waters, or TA, or clinical in the past will now be applied to the new divisions in the same way.

    這也是我們過去做過的事情。因此,我們在 Waters、TA 或過去臨床業務所看到的定價紀律,現在也會以同樣方式套用到新的事業部。

  • So there will be commercial investment to ensure operational excellence, be it on launch readiness, be it on pricing. And equally, we've looked at separately the amount of resources that are going after the launches. Be it the FXI on the microbiology business, be it BD Core, where it is enhancing HPV testing across the overall population.

    所以我們會進行商業端投資,以確保營運卓越,不論是在上市準備度或定價方面。同樣地,我們也另外檢視了投入在產品上市上的資源量。不論是微生物業務的 FXI,或是 BD Core(核心),其目標是在整體人群中提升 HPV 檢測。

  • Or on the flow cytometry side, we've taken specialists and move them into the different businesses equally investing further in commercial readiness. So we feel pretty good about the resources we've put against improving the execution rhythm but also getting a stronger uptake of the new products.

    或者在流式細胞儀(flow cytometry)方面,我們把專家調派到不同業務中,同時也進一步投資於商業準備度。因此我們對於投入的資源感到相當有信心:既能改善執行節奏,也能讓新產品有更強的採用動能。

  • Matt Larew - Analyst

    Matt Larew - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Casey Woodring, JPMorgan.

    Casey Woodring,JPMorgan。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Great. Thank you for taking my questions. So another strong quarter of chemistry performance. Curious if you could just unpack that for us. How much of that was price? How much was new product contribution in bioseparations?

    很好。謝謝回答我的問題。化學業務又是一個強勁的季度表現。想請你們幫我們拆解一下。其中有多少來自價格?有多少來自生物分離(bioseparations)新產品的貢獻?

  • As a follow-up on pricing, can you just elaborate -- you had talked about, I think it was 100 basis points to 200 basis points of pricing improvement with a high stick rate in that business. So how do you see pricing evolving here in chemistry within that 6%, 2026 guidance framework?

    另外追問定價,你們之前提到該業務的定價改善大約是 100 到 200 個基點,而且價格落地率很高。那麼在化學業務這裡,在你們 2026 年 6% 指引框架下,你們如何看待定價的演變?

  • Thank you.

    謝謝。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Let me start with this, Casey, and Amol will elaborate. Look, very happy with what we're seeing on chemistry, 12% growth for the year. Seeing really nice momentum already in Q1 with the innovation. And I mean, basically, it's a mix of what you just mentioned earlier. These are highly innovative products that command a price premium.

    Casey,我先從這裡開始,Amol 會再補充。你看,我們對化學業務目前看到的狀況非常滿意,今年成長 12%。在第一季就已經看到創新帶來很好的動能。而且基本上,就是你剛才提到的那些因素的組合。這些都是高度創新的產品,能夠取得價格溢價。

  • From a pipeline and product perspective, as I mentioned in the prepared remarks, we've built on the Max peak Premier technology, which is -- which targets -- surfaces of all types. With SEC columns, with oligonucleotides, with slalom chromatography, and sort of the newest kid on the block is the affinity chromatography where we're attaching antibodies to particles.

    從產品管線與產品的角度來看,正如我在事先準備的發言中提到的,我們是在 Max peak Premier 技術的基礎上持續建構;該技術可用於——也就是針對——各種類型的表面。搭配 SEC 色譜柱、寡核苷酸、slalom 色譜,而目前最新、最受矚目的則是親和層析(affinity chromatography),我們會把抗體接到顆粒上。

  • And here, super excited about what's going to come from BD with the capability in biology and antibody preparation, so we can prepare specific antibodies to conjugate to our particle. So we feel very good about what's been happening and a nice momentum already at the start of the year. Amol, do you want to talk about pricing?

    在這方面,我們對 BD 未來能帶來的成果非常興奮,因為他們在生物學與抗體製備方面具備能力,讓我們可以製備特異性抗體並與我們的顆粒進行偶聯。因此,我們對目前的進展感到非常樂觀,而且在年初就已經有不錯的動能。Amol,你要談一下定價嗎?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah. I mean on chemistry alone Casey, as we had outlined chemistry, we are able to get an amazing stick rate on our list price increases. So for like-for-like SKU, like-for-like geography, we are generating close to 400 basis points, 450 basis points on chemistry. On the overall portfolio basis, we're generating about 200 basis points of like-for-like SKU, like-for-like geography. That doesn't include upsell, and that's sort of running ahead of what we outlined at our Investor Day.

    好的。我是說,單就化學產品而言,Casey,正如我們先前所說明的化學業務,我們在名目表價調漲上的落地率(stick rate)非常驚人。因此,以同款 SKU、同一地理區域的可比口徑來看,我們在化學產品上帶來接近 400 個基點、450 個基點的提升。以整體產品組合口徑來看,我們在同款 SKU、同一地理區域的可比口徑下,大約帶來 200 個基點。這還不包含向上銷售(upsell),而且目前的表現其實超前我們在投資人日所提出的指引。

  • But more critically, that's a significant opportunity that lies ahead of us for BD. Remember, because Waters back pre-COVID was 50-ish basis points of year-over-year price and now we are consistently delivering 200 basis points plus. And BD is exactly that, right? Like historically, they've done somewhere between 40 basis points to 50 basis points and a meaningful opportunity ahead of us to reapply our blueprint that has been so successful.

    但更關鍵的是,這對 BD 而言是我們前方一個重大的機會。請記得,Waters 在 COVID 之前的年對年價格提升大約只有 50 個基點左右,而現在我們穩定交付 200 個基點以上。而 BD 也是同樣的情況,對吧?他們歷史上大概做到 40 到 50 個基點,而我們前方有很有意義的機會,去重新套用我們已被證明非常成功的藍圖。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Puneet Souda, Leerink.

    Puneet Souda,Leerink。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Yeah, hi, Amal and Casper, thanks for taking my question. If I could circle back to an earlier question around the conservatism you're taking in the acquired assets growth. Obviously, those numbers are lower versus the expectations you had earlier. I understand that you're baking in pricing and KPI discipline that you're going to bring about.

    是的,你好,Amal 和 Casper,謝謝你們回答我的問題。如果我可以回到先前關於你們在併購資產成長上採取較保守假設的問題。顯然,這些數字比你們先前的預期要低。我理解你們把定價與 KPI 紀律納入了你們將要導入的作法。

  • But you are in markets that are different to what pharma QA/QC have been. So maybe just -- I would love to understand if you could, how much of a cushion there is in these numbers?

    但你們所處的市場,與藥廠 QA/QC 過去的市場不同。所以也許——我很想了解的是,如果可以的話,這些數字裡面有多少緩衝空間(cushion)?

  • How adjusted are they? If you could give us a sense, because I think that's the number one question we're getting from investors as to the prudence you're baking in for the acquired portfolio.

    它們調整到什麼程度?如果你們能給我們一些感覺,因為我認為這是投資人最常問的第一個問題:你們在併購組合上所納入的審慎程度到底有多高。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • So let me start, and then Amol will give you the parts. Look, I mean, we're not baking in just to sort of correct the question itself. We're not baking in the pricing improvements, or the deal desk and the launch readiness into the numbers. Amol, do you want to describe the details?

    我先開始,然後 Amol 會補充細節。你看,我的意思是,我們並沒有把——先更正一下問題本身。我們並沒有把定價改善、或是 deal desk(交易支援/報價審核機制)以及上市準備度(launch readiness)納入這些數字。Amol,你要描述一下細節嗎?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. I mean, look, we are baking in primarily the headwind from China [TRC] And at this point, it's only prudent to sort of take that in. And we are also baking in some continued slowness coming out of other elements that are associated with China, or the academic and government market. But again, when you look at our own water stand-alone US A&G performance, it's tale of two worlds, right?

    是的。我的意思是,你看,我們主要納入的是來自中國的逆風 [TRC],而在目前這個時間點,把這點納入是審慎的作法。我們也納入了與中國相關的其他因素所帶來的持續放緩,或是學術與政府市場的放緩。但再說一次,當你看我們 Waters 單體在美國 A&G(學術與政府)市場的表現時,這其實是兩個世界的故事,對吧?

  • So there is a clear meaningful upside. If we can reapply our success to some of these parts, like what we've done in China, like what we've done with US A&G. But at the beginning of the year, right out of the gate, we want to be prudent.

    所以這裡有很明顯且相當可觀的上行空間。如果我們能把我們的成功經驗重新套用到其中一些部分,例如我們在中國做過的、或我們在美國 A&G 做過的。但在年初、剛起步的時候,我們希望保持審慎。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Got it. That's helpful. And then was there any contribution from extra selling days in Q1 that you're contemplating?

    了解。這很有幫助。另外,你們在 Q1 是否有考量額外的銷售天數所帶來的貢獻?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • So I mean, our Q1 guide reflects four extra working days.

    所以,我們的 Q1 指引反映了額外 4 個工作天。

  • Operator

    Operator

  • Subu Nambi, Guggenheim.

    Subu Nambi,Guggenheim。

  • Subu Nambi - Analyst

    Subu Nambi - Analyst

  • Hey guys, thank you for taking my question. What does operating margin progression look like this year with the addition to BD? What prudence is in those risk-adjusted assumption given it's a cleaner base?

    嗨,各位,謝謝你們回答我的問題。在納入 BD 之後,今年的營業利益率(operating margin)推進會是什麼樣子?鑑於基期更乾淨,你們在那些風險調整後假設中納入了哪些審慎因素?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yeah. Look, I mean, as we came into fourth quarter, we said we have few strategic R&D investments that could accelerate growth, particularly in bioseparations and informatics, and you're seeing the results of that growth on our top line. So we took the opportunity to accelerate some of those investments without changing our long-term margin on algorithm, right?

    是的。你看,我的意思是,當我們進入第四季時,我們說過有一些策略性的研發投資可以加速成長,特別是在生物分離(bioseparations)與資訊學(informatics)方面,而你們也在我們的營收端看到了這些成長成果。因此,我們把握機會加速其中一些投資,但並沒有改變我們長期的利益率演算法(margin algorithm),對吧?

  • So coming into 2026, we're back to 31.3%, which we feel really good about. And the BD Biosciences and Diagnostic Solutions business is coming in at 22.4%.

    所以到了 2026 年,我們回到 31.3%,我們對此感覺非常好。而 BD 的 Biosciences 與 Diagnostic Solutions 業務的利益率是 22.4%。

  • So net of revenue and cost synergies that allows us to deliver 28.1% margin, which is perfectly in line with how we announced the deal where we said, look, we'll expand the margin of the pro forma company from 27% to 32% over five years. And where we are coming in on 2026 is exactly in line with the lower 100 basis points in the first year.

    因此,在納入營收與成本綜效之後,我們可以交付 28.1% 的利益率,這與我們宣布交易時所說的完全一致:我們會在五年內把合併後(pro forma)公司的利益率從 27% 擴張到 32%。而我們在 2026 年的落點,正好符合第一年較低的 100 個基點擴張。

  • Operator

    Operator

  • This concludes the Q&A portion of the call. I will now hand it back to Udit.

    本次電話會議的問答部分到此結束。我現在把時間交回給 Udit。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Thank you. Look, I mean guys, thank you very much for your attention today. As we get into the new chapter for Waters, we're starting our guidance for 2026, with, again, an industry-leading growth for the pro forma business.

    謝謝。各位,我非常感謝大家今天的關注。隨著 Waters 進入新的篇章,我們開始提供 2026 年的指引;同樣地,合併後(pro forma)業務將展現業界領先的成長。

  • Really coming out of the gate strong on operational execution and synergies with $55 million on cost and $50 million on revenue side, which yields 100 basis points of margin expansion already in year one, and almost a 1% accretion in less than a year. So I feel very good about where we're starting.

    我們在營運執行與綜效上,確實是一開始就強勢起跑:成本端 5,500 萬美元、營收端 5,000 萬美元,這使得第一年就能帶來 100 個基點的利益率擴張,並且在不到一年內帶來接近 1% 的增益(accretion)。所以我對我們的起點感到非常樂觀。

  • Thank you very much for your support and look forward to talking to you again.

    非常感謝你們的支持,也期待再次與各位交流。